- Home
- LANV vs XGN Comparison
LANV vs XGN Comparison
Compare LANV & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LANV
- XGN
- Stock Information
- Founded
- LANV 2015
- XGN 2002
- Country
- LANV China
- XGN United States
- Employees
- LANV N/A
- XGN N/A
- Industry
- LANV Blank Checks
- XGN Medical Specialities
- Sector
- LANV Finance
- XGN Health Care
- Exchange
- LANV Nasdaq
- XGN Nasdaq
- Market Cap
- LANV 244.4M
- XGN 210.4M
- IPO Year
- LANV N/A
- XGN 2019
- Fundamental
- Price
- LANV N/A
- XGN $10.95
- Analyst Decision
- LANV
- XGN Strong Buy
- Analyst Count
- LANV 0
- XGN 5
- Target Price
- LANV N/A
- XGN $12.40
- AVG Volume (30 Days)
- LANV 51.5K
- XGN 248.9K
- Earning Date
- LANV 08-29-2025
- XGN 11-11-2025
- Dividend Yield
- LANV N/A
- XGN N/A
- EPS Growth
- LANV N/A
- XGN N/A
- EPS
- LANV N/A
- XGN N/A
- Revenue
- LANV $341,783,911.00
- XGN $58,862,000.00
- Revenue This Year
- LANV N/A
- XGN $22.28
- Revenue Next Year
- LANV $6.90
- XGN $14.03
- P/E Ratio
- LANV N/A
- XGN N/A
- Revenue Growth
- LANV N/A
- XGN 3.89
- 52 Week Low
- LANV $1.32
- XGN $2.38
- 52 Week High
- LANV $2.69
- XGN $11.17
- Technical
- Relative Strength Index (RSI)
- LANV 51.70
- XGN 63.77
- Support Level
- LANV $2.02
- XGN $10.63
- Resistance Level
- LANV $2.18
- XGN $11.11
- Average True Range (ATR)
- LANV 0.12
- XGN 0.40
- MACD
- LANV 0.01
- XGN 0.02
- Stochastic Oscillator
- LANV 56.00
- XGN 82.85
About LANV Lanvin Group Holdings Limited
Lanvin Group Holdings Ltd engages in offering products ranging from apparel to leather goods, footwear, and accessories. The firm is operating mainly 5 portfolio brands, namely Lanvin, Wolford, Sergio Rossi, St. John, and Caruso. It derives the majority of its revenue from the Wolford segment.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.